ARPINO, GRAZIA
ARPINO, GRAZIA
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
2007 Arpino, Grazia; Carolina, Gutierrez; Heidi, Weiss; Mothaffar, Rimawi; Suleiman, Massarweh; Lavina, Bharwani; DE PLACIDO, Sabino; C., Kent Osborne; Rachel, Schiff
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M.
Triple-negative breast cancers: Biomarkers and outcomes
2010 Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts.
2006 M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff
Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer
2003 Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies
2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
2005 Xiaojiang, Cui; Rachel, Schiff; Arpino, Grazia; C., Kent Osborne; Adrian V., Lee
Capitolo 4 - Terapia Medica
2011 G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco
Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy.
2002 V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark
The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy.
2003 Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer
2002 Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition.
2004 Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R.
HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study
2002 Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance
2003 Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge
Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance.
2004 Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm
GMO-Gestione Malattie Oncologiche in Regione Campania.
2011 Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes
2005 Arpino, Grazia; H., Weiss; R., Elledge
Prognostic and predictive factors in breast cancer, an evidence-based medicine approach
2002 Mohsin, Sk; Bardou, Vj; Arpino, Grazia; Chamness, Gc; Allred, Dc
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, Rm
Health-care costs associated with breast cancer management
2010 Cammarota, S.; Citarella, A.; Menditto, Enrica; Putignano, D.; Riegler, S.; De Luca, L.; Malorni, L.; DE PLACIDO, Sabino; Arpino, Grazia
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. | 1.1 Articolo in rivista | 2007 | Arpino, Grazia; Carolina, Gutierrez; Heidi, Weiss; Mothaffar, Rimawi; Suleiman, Massarweh; Lavina, Bharwani; DE PLACIDO, Sabino; C., Kent Osborne; Rachel, Schiff | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M. | |
| Triple-negative breast cancers: Biomarkers and outcomes | 4.1 Articoli in Atti di convegno | 2010 | Malorni, L.; Shetty, P. B.; Hilsenbeck, S. G.; Rimawi, M. F.; Elledge, R. M.; De Angelis, C.; Osborne, C. K.; DE PLACIDO, Sabino; Arpino, Grazia | |
| Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. | 4.1 Articoli in Atti di convegno | 2006 | M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff | |
| Predictive value of apoptosis, proliferation, and HER-2 for anthracycline chemotherapy in patients with locally advanced breast cancer | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; D. R., Ciocca; H., Weiss; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S., Mohsin | |
| HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies | 1.5 Abstract in rivista | 2002 | DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco | |
| Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. | 1.1 Articolo in rivista | 2005 | Xiaojiang, Cui; Rachel, Schiff; Arpino, Grazia; C., Kent Osborne; Adrian V., Lee | |
| Capitolo 4 - Terapia Medica | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | G., Tortora; F., Ciardiello; Arpino, Grazia; A. R., Bianco | |
| Progesterone receptor (PgR) status provides additional information to estrogen receptor (ER) status for predicting clinical outcomes of primary breast cancer patients treated with adjuvant endocrine therapy. | 4.1 Articoli in Atti di convegno | 2002 | V. J., Bardou; Arpino, Grazia; R. M., Elledge; G. M., Clark | |
| The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy. | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne | |
| Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge | |
| Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R. | |
| HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer; a SWOG study | 4.1 Articoli in Atti di convegno | 2002 | Arpino, Grazia; S., Green; Dc, Allred; P., Ravdin; D., Lew; S., Martino; Ck, Osborne; R., Elledge | |
| Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance | 4.1 Articoli in Atti di convegno | 2003 | Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance. | 4.1 Articoli in Atti di convegno | 2004 | Arpino, Grazia; Weiss, H; Lee, A; Schiff, R; Osborne, Ck; Elledge, Rm | |
| GMO-Gestione Malattie Oncologiche in Regione Campania. | 2.1 Contributo in volume (Capitolo o Saggio) | 2011 | Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino | |
| Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes | 4.1 Articoli in Atti di convegno | 2005 | Arpino, Grazia; H., Weiss; R., Elledge | |
| Prognostic and predictive factors in breast cancer, an evidence-based medicine approach | 2.1 Contributo in volume (Capitolo o Saggio) | 2002 | Mohsin, Sk; Bardou, Vj; Arpino, Grazia; Chamness, Gc; Allred, Dc | |
| Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. | 1.1 Articolo in rivista | 2005 | Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, Rm | |
| Health-care costs associated with breast cancer management | 1.5 Abstract in rivista | 2010 | Cammarota, S.; Citarella, A.; Menditto, Enrica; Putignano, D.; Riegler, S.; De Luca, L.; Malorni, L.; DE PLACIDO, Sabino; Arpino, Grazia |